Sung Won Song
Direttore/Membro del Consiglio presso JW (CAYMAN) THERAPEUTICS CO. LTD
Posizioni attive di Sung Won Song
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
| JW (CAYMAN) THERAPEUTICS CO. LTD | Direttore/Membro del Consiglio | 29/08/2023 | - |
EpimAb Biotherapeutics, Inc.
 EpimAb Biotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology EpimAb Biotherapeutics, Inc. is a Chinese clinical stage biopharmaceutical company that specializes in developing multispecific antibodies. The company is based in Shanghai, China. The company utilizes its in-house research and technology capabilities, including the proprietary fit-ig® and mat-fab bispecific platforms, to generate and advance a unique pipeline of transformative preclinical and clinical assets that aim to benefit cancer patients. The company was founded in 2016 by Chen Bing Wu, who has been the CEO since 2016. | Direttore/Membro del Consiglio | - | - |
Storia della carriera di Sung Won Song
Formazione di Sung Won Song
| Korea University | Undergraduate Degree |
| The Trustees of Columbia University in The City of New York | Graduate Degree |
| The Ohio State University | Doctorate Degree |
Statistiche
Distribuzione geografica
| Cina | 3 |
| Stati Uniti | 3 |
| Corea del Sud | 2 |
Posizioni
| Director/Board Member | 2 |
| Undergraduate Degree | 1 |
| Graduate Degree | 1 |
Settori
| Consumer Services | 4 |
| Health Technology | 3 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| JW (CAYMAN) THERAPEUTICS CO. LTD | Health Technology |
| Aziende private | 1 |
|---|---|
EpimAb Biotherapeutics, Inc.
EpimAb Biotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology EpimAb Biotherapeutics, Inc. is a Chinese clinical stage biopharmaceutical company that specializes in developing multispecific antibodies. The company is based in Shanghai, China. The company utilizes its in-house research and technology capabilities, including the proprietary fit-ig® and mat-fab bispecific platforms, to generate and advance a unique pipeline of transformative preclinical and clinical assets that aim to benefit cancer patients. The company was founded in 2016 by Chen Bing Wu, who has been the CEO since 2016. | Health Technology |
- Borsa valori
- Insiders
- Sung Won Song
- Esperienza
